Olea's Response by Olea, Nicolas
)ndegnce-
Comments on "Estrogenicity
of Resin-based Composites
and Sealants Used in
Dentistry"
Considerable concerns about bisphenol A
(BPA) as a potential endocrine disruptor
remain controversial among dentists and
patients due to the study ofOlea et al. (1).
Their study has frequently been mentioned
in scientific papers as well as in the mass
media, popular journals, and books. When
I read the paper, I was shocked to find
unscientific data related to high perfor-
mance liquid chromatography (HPLC)
analysis. I am concerned about continued
reference to this study. Ashby (2) com-
mented on the study in a letter in EHP
titled "Bisphenol-A Dental Sealants: The
Inappropriateness of Continued Reference
to a Single Female Patient," but I feel his
comments are insufficient.
Olea et al. (1) reported that 90-931 pg
of BPA was identified in saliva collected
from 18 subjects treated with 50 mg of a
bisphenol A diglycidyl methacrylate (bis-
GMA)-based sealant on molars during a 1-
hr period after treatment. However, based
on data presented in their Table 1, this is
unlikely. According to Table 1 (1), 50 mg
ofthe sealant should contain 3.7 pgofBPA
or 78.7 pg of a mixture of bis-GMA,
bisphenol A diglycidyl ether (BADGE),
bisphenolAdimethacrylate (BPDMA), and
BPA. This mixture (78.7 pg) is equivalent
to 48.2 pg of BPA. Assuming that all the
components of the mixture leached into
the saliva uncured and were degraded com-
pletely to BPA within 1 hr, the amount of
BPA collected from the saliva should be
48.2 pg. However, their Table 2 (1)
showed 1.9-19.3-fold higher values than
expected (89.9-931.0 pg).
In the "Results," Olea etal. (1) reported
that
A subject initially selected for treatment had been
treated with tooth sealant 2 years earlier; chro-
matograms demonstrated the presence ofbisphe-
nol-A (66.4 pg) and bisphenol-A dimethacrylate
(49.2 pg) in her saliva before the second treat-
ment. The results from this subject were excluded
from analysis.
This finding suggested that 66 pg/hr of
BPA may be continually released over 2
years. This is unlikely because the treat-
ment would have been practically impossi-
ble. Assuming that 66 pg of BPA leached
into the saliva daily, leaching of BPA
would have constituted 48.2 mg over 2
years. The BPA content in the sealant was
0.0074% according to their data.
Therefore, the original amount of sealant
used would have been about 650 g. Even if
BPDMA, which is easily hydrolyzed to
BPA, is included in the calculation, it
would have been approximately 200 g.
In their Table 1, Olea et al. (1) indicat-
ed that the amount ofethanol-soluble com-
ponents in the composite resins and the
sealant was 0.03-0.19% (calculated from
the total weight offour components shown
in Table 1 contained in 100 mg of com-
mercial product). These values are much
too small because commercial resins usually
contain 15-50% of ethanol-soluble com-
ponents. Olea et al. (1) stated that
these commercial formulations contain a large
proportion of inorganic filler particles (50-85%
byweight ofthe composite).
Moreover, they did not refer to triethyl-
ene glycol dimethacrylate (TEGDMA),
which is a major component in all these
commercial products. Assuming that their
data were correct, some questions arise: a)
BPA contents in the ethanol-soluble compo-
nents [most ofwhich consist ofa mixture of
bis-GMA (and BPDMA) and TEGDMA]
were much too high-1.7-35.2% (calculat-
ed from the ratio ofBPA to the total weight
of four components). Such impure
monomers are unlikely in the chemical
industry at the present time. BPA may exist
in the monomers as an impurity. b) The
total amounts of ethanol-soluble compo-
nents markedly increased or decreased in
many cases after hydrolysis in alkaline or
acidic media beyond the values expected
from the contents before hydrolysis. This
should not occur in a chemical reaction; the
reaction should follow the law of conserva-
tion ofmass. c) The increase in the BPDMA
content in alkaline media for composites 1
and 2 is unlikely because it is easily
hydrolyzed to BPA in the media. a) The
marked increase in bis-GMA content after
hydrolysis in acidic or alkaline media, com-
posite 3, is unlikely because bis-GMA is
hydrolyzed undersuch conditions.
The calculation presented in Olea and
colleagues' Table 2 (1) is difficult to
understand. The saliva volume multiplied
by the concentration of BPA should be
equal to the total amount ofBPA in saliva.
None of the data presented in their Table
2 supported this arithmetic.
Olea et al. (1) may have misunderstood
that BPA (as well as BADGE) constitutes
components of resins, judging from the
statement in the first paragraph of the
"Discussion":
... we demonstrate that [BPA] and [BPDMA],
components ofcommercial resin-based compos-
ites and sealants used in dentistry, are estro-
genic ....
BPA and BADGE are not components,
but only a trace amount ofthese materials
is contained as impurities in bis-GMA
and/or BPDMA monomers. Therefore, the
amount ofleached BPA is extremely small
or not detectable, as reported recently by
other investigators (3-5). On the other
hand, BPDMA is a component of the
sealant used in their study. Therefore,
leaching ofa small amount ofunpolymer-
ized BPDMA is likely (3,4). Furthermore,
the detection of BPA derived from
BPDMA in saliva is likely because
BPDMA is easily hydrolyzed to BPA in
saliva (6). Thus, it is reasonable to assume
that most ofthe BPA identified in saliva by
Olea et al. (1) can be attributed to leached
BPDMA. Therefore, the use of BPDMA
should be extensively examined.
Data relevant to HPLC analysis pre-
sented by Olea et al. (1) are not reliable.
These data should be corrected or with-
drawn, and further reference to this data
should be avoided.
Yohji Imai
Institute for Medical and
Dental Engineering
Tokyo Medical and Dental University
Tokyo, Japan
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Olea's Response
Imai seems to be upset about our recom-
mendation to curtail the use of bisphenol
A-based sealants and daims to have found
unscientific data among our HPLC results.
His opinions appear to be based on a poor
reading ofour study (1) and what he refers
to as "relevant papers." Unfortunately, Imai
reveals no data of his own and reports no
experiments or time spent actuallytrying to
solve this problem.
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Three of the references provided by
Imai are only abstracts (2-4), one in
Japanese, precluding a full reading and criti-
cal analysis. The article by Nathanson et al.
(5) elicited a detailed response from our
group in the form ofa letter, which the edi-
tor of the Journal ofthe American Dental
Association (JADA) declined to publish,
despite our insistence and repeated submis-
sion ofever shorterversions.
Thus, we consider this an appropriate
opportunity to respond to both Imai and
Nathanson, given the importance of our
findings for the practice ofdentistry and as
a public health issue. The work by
Nathanson et al. (5) was largely devoted to
refuting our paper on the estrogenicity of
pit and fissure sealants (1). Their claim that
their findings on leachability contradict our
results implies that the two studies are com-
parable, while in fact their study differs
substantially from ours. First, Nathanson's
paper (5) does not test the estrogenicity of
sealant eluates, although the demonstration
of estrogenic compounds leaching from a
sealant was the most important finding of
our study, a point that was also ignored by
Imai. The nature of these compounds
could be diverse because several compo-
nents of commercial sealants have been
identified as estrogenic xenobiotics. We
postulated that bisphenol A and the
dimethacrylate of bisphenol A (bisDMA)
are candidates for this hormonal effect, but
the presence of other chemicals contribut-
ing to this effect cannot be ruled out.
We reported that BPA leached from
unpolymerized sealant after heating
(100°C) and was found in the saliva of
patients after in situ polymerization. Data
we presented (Table 1) on the content of
BPA, BADGE, and bisDMA in one sealant
and three composites, of concern to Imai,
are indicative ofthe presence ofthese com-
pounds in the commercial samples. As Imai
comments, an exhaustive analysis of these
samples reveals that the values we reported
"are much too small because commercial
resins usually contain 15-50% of ethanol-
soluble components." We did not study the
entire content of components in the com-
mercial samples, but we did identify the
source ofthe monomers found in the saliva
of treated patients. Most of the discrepan-
cies asserted by Imai are due to his idiosyn-
cratic reading ofthe experimental data. For
example, we did not mention "ethanol-sol-
uble components" for the simple reason
that all the extracts tested were water solu-
ble. Moreover, to estimate leaching over
time by extrapolating from our results, as
Imai attempts to do, is not warranted.
We chose to explore sealant polymeriza-
tion within the mouth because this is where
polymerization is done in practice. In con-
trast, Nathanson et al. (5) polymerized the
material in vitro. Success ofthe polymeriza-
tion process is clearly dependent on the
microenviromental conditions: saliva,
humidity, access to curing light, etc. These
differences in experimental conditions pre-
vent comparisons between the two papers.
In fact, despite their different approach,
Nathanson et al. (5) did show that bisDMA
leached into the eluates ofDelton (Dentsply
Trubyte, York, PA) and Defender (Henry
Schein, Inc., Melville, NY) sealants, and the
amount of bisDMA leached by Delton
sealant over 4 min (1.3 pg/mg of sealant)
greatly exceeded the maximum amount
recovered during 1 hr from the saliva ofthe
three patients presenting detectable amounts
ofbisDMA (0.063 pg/mg ofsealant) in our
study. Nathanson et al. (5) found no BPA
leaching from anyofthe sealants they tested.
In contrast, we found BPA in the saliva of
patients treated with Delton sealant at con-
centrations ranging from 1.8 to 18 pg/mg of
sealant applied. In addition to the site ofthe
polymerization process, other technical dif-
ferences may account for these discrepancies.
For example, Nathanson et al. (5) used a
wavelength of 215 nm for the detection of
sealant moieties separated by HPLC. Lineal
dimethacrylate derivatives such as
TEGDMA that absorb at this wavelength
maybe detected in this protocol. In contrast,
by using a 280-nm wavelength, we detected
BPA and other aromatic monomers such as
BADGE, bisDMA, and bis-GMA, without
interference from lineal ethyleneglycol
dimethacrylate derivatives. Furthermore,
Nathanson et al. (5) offer curious details.
For example, in the "Material and
Methods," they stated that the GC/MS
technique was done using a "DB-5 HPLC
column of30 m." As far as we know, and as
confirmed byJ&W Scientific (Folsom, CA),
no such column exists. It is difficult to assess
what "Unknown I" peak represents because
it is incorrect to "calculate the amount of
Unknown I by using the BisGMA standard
solution as the reference because their spec-
tra are similar," as they did. The chromato-
graphic data are inadequate because
* No calibration curves were are shown for
any of the compounds analyzed; more-
over, the authors did do not mention any
parameters ofthese curves, neither fit nor
correlation coefficients
* No indication oflinearity ofthe detector
response is presented
* No information about the accuracy of
the chromatographic curve is provided
* The percentage of recovery for the stan-
dard curves is not reported
* The practice of confirming peaks by
addition is of dubious reliability; instead,
GC/MS should be used to identify all
unknown peaks.
Retention times in HPLC are not valid for
identification. These technical shortcom-
ings make it difficult to compare data.
We think that more data should be
gathered before adopting the complacent
position proposed by Nathanson et al. (5)
and Imai. Recent observations have raised
concerns about the estrogenicity ofbisphe-
nols (6-11): a) a more potent in vivo effect
of BPA than that assessed by previous in
vitro assays has been demonstrated (6,7);
b) BPA seems to act on target organs other
than breast and uterus (6,8-10); c) genetic
differences in susceptibility to the estro-
genic effect of BPA have increased con-
cerns about human subpopulations with a
higher sensitivity to this estrogen (6,11);
and ac) bisphenol A is just one of many
compounds used by the plastics industry
with demonstrated in vitro estrogenicity
(12). By taking these studies into account,
the American Dental Association may con-
sider adopting a more realistic position
regarding the use ofbis-GMA-based com-
posites and sealants, as recently suggested
by Soderholm and Mariotti (13).
In short, the flaws in the paper by
Nathanson et al. (5) undermine its conclu-
sions on the safety of sealants; we regret
theJADA Editor-in-Chiefs decision not to
publish our rebuttal to the allegations of
Nathanson's group. Imai should not have
used these flawed data to support his
attack on our work. Dental health profes-
sionals ought to be aware of the potential
risks ofhormonally active compounds pre-
sent in these formulations. Suppliers and
other stakeholders should also be encour-
aged to address this public health issue.
Until data are provided that challenge our
data and arguments, the hypothesis of
human exposure to estrogenic compounds
leaching from bis-GMA-based composites
cannot be withdrawn.
Nicolas Olea
Department ofRadiology
University ofGranada Laboratory
Medical Investigations
Granada, Spain
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Error in DEHP Background
Concentration
In the May 1998 issue of Environmental
Health Perspectives, Woodruff et al. (1)
reported an analysis conducted as part of
the U.S. Environmental Protection Agency
(EPA) Cumulative Exposure Project
(CEP). The EPA modeled air concentra-
tions of chemicals listed in the Clean Air
Act as hazardous air pollutants (HAPs) in
over 60,000 census tracts and compared
those concentrations to health benchmarks.
The Phthalate Esters Panel ofthe Chemical
Manufacturers Association has become
aware of an error in the background con-
centration value used for bis(2-ethylhexyl)
phthalate (DEHP), with the result that
modeled air concentrations for DEHP-
and thus the potential health hazard-were
greatly exaggerated.
Woodruff et al. (1) reported, "Eight
pollutants ... [including DEHP] had mod-
eled concentrations exceeding the bench-
mark concentrations for cancer in 100% of
the census tracts. For each of these HAPs,
the background concentration alone ...
exceeded the benchmark concentration for
cancer, as shown in Table 2." Their Table
2 (1) shows that the background concentra-
tion used for DEHP was 1.6 pg/m3. That
value was taken from Howard (2) who
reported "mean remote ocean air concen-
trations" for DEHP of 0.07-0.17 ppb, cit-
ing Atlas and Giam (3). However, Atlas
and Giam (3) actually reported remote
DEHP air concentrations to be 0.32-2.68
ng/m3, with a mean of 1.4 ng/m3 a value
more than 1,000 times less than the back-
ground value used for the CEP analysis.
The panel has alerted the EPA to this error,
and the EPA accordingly has corrected the
CEP modeling report (4).
TIable 2 of Woodruff et al. (1) shows
that if the erroneous background value of
1.6 pg/m3 is disregarded, the CEP model
predicts DEHP air concentrations to
exceed the health benchmark of 0.25
pg/m3 in only 18 census tracts. Even this
estimate probably exaggerates the potential
health hazard for two reasons. First, to the
panel's knowledge, the highest measured
ambient DEHP air concentration in the
United States that has been reported in the
literature is 28 ng/m3 (5)-an order of
magnitude below the EPA's cancer health
benchmark. Second, the EPA's health
benchmark of 0.25 pg/m3 was derived
using an upper-bound unit risk methodolo-
gy to extrapolate tumor data in rats and
mice to human risk (6,7). However,
numerous investigators now conclude that
peroxisome proliferators such as DEHP
pose little ifany human cancer risk and that
the quantitative risk assessment for such
compounds should be based on a margin of
exposure approach (8-10). This would sig-
nificantly increase the health benchmark
for DEHP and decrease (probably to zero)
the number ofcensus tracts in which mod-
eled air concentrations would exceed the
health benchmark.
Courtney M. Price
CHEMSTAR
Arlington, Virginia
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DEHP Correction
We thank Courtney Price for pointing out
an error in the background concentration for
bis(2-ethylhexyl)phthalate (DEHP) in our
paper "Public Health Implications of 1990
Air Toxics Concentrations across the United
States" (1). In this paper, emissions data
from stationary and mobile sources are used
in an atmospheric dispersion model to esti-
mate outdoor concentrations of 148 toxic air
contaminants for each of the 60,803 census
tracts in the contiguous United States.
Outdoor concentrations of air toxics were
compared to previously defined benchmark
concentrations for cancer and noncancer
health effects. Benchmark concentrations are
based on standard toxicological references
and represent air toxic levels above which
health risks may occur.
The results reported for DEHP are
incorrect due to an error in the estimated
background concentration for DEHP. We
had originally used a value of 1.6 pg/m3 for
DEHP, which was reported by Howard
(2). As pointed out by Price, Howard (2)
had incorrectly reported the value from
another source, Atlas and Giam (3).
Consequently, we have revised the back-
ground concentration for DEHP to 0.0014
pg/m3, consistent with the mean value
reported byAtlas and Giam.
We had reported that the background
concentration for DEHP was greater than
the cancer benchmark for DEHP. However,
the revised background concentration is
much lower than the cancer benchmark.
Thus, DEHP should not be included in the
list ofpollutants in Table 2 for which back-
ground concentrations alone exceeded can-
cer benchmark concentrations (1). The
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